Longitudinal study on lung health in young adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The ALA Lung Health Cohort is a multi-center observational study enrolling around 4,000 young adults aged 25-35 without severe lung disease. The study aims to explore the relationship between various factors such as environmental exposures, physical activity, and biomarkers on lung health. Participants will undergo baseline assessments and receive regular follow-ups over 4.5 years to gather data on their lung health. If additional funding is secured, the study may extend to investigate long-term changes in lung health beyond five years.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1- Age 25-35 years at the time of the baseline examination 2- Able to read and understand English or Spanish 3 -Has a social security number 4- Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination. Note: Individuals who are residents of the US who have temporarily spent time living outside of the US during the last 12 months (e.g., student exchange program, military posting) are eligible for participation.

5- Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant

Exclusion Criteria:

1. Severe asthma, which is defined as any of the following:

   1. Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; Medium dose = \>250 fluticasone, propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS.

      OR
   2. 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months OR
   3. One asthma hospitalization in the past 12 months
2. History of any chronic lung disease other than asthma including but not limited to COPD, cystic fibrosis, pulmonary fibrosis, pulmonary hypertension
3. Current pregnancy
4. History of cancer other than non-melanoma skin cancer
5. Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease)
6. Inability to comply with study procedures, including

   1. Inability or unwillingness to provide informed consent
   2. Inability to perform study measurements
   3. Inability to be contacted by phone (via calls and/or text messaging) or email
7. Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit).
8. Institutionalization

Where it's running

• University Of Alabama
  Birmingham, Alabama, United States Recruiting
• University of Arizona-Tuscon
  Tucson, Arizona, United States Recruiting
• University of California, Los Angeles
  Los Angeles, California, United States Recruiting
• University of California, San Francisco
  San Francisco, California, United States Recruiting
• National Jewish Health
  Denver, Colorado, United States Recruiting
• Nemours Children's Jacksonville
  Jacksonville, Florida, United States Recruiting

Study contacts

• Principal investigator: Ravi Kalhan, MD — Northwestern University
• Study coordinator: Elizabeth Sugar, PhD
• Email: esugar2@jhu.edu
• Phone: 443-287-3170

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Electrical Impedance Tomography for Monitoring Lung Disease

  This test tries to see if a painless, noninvasive imaging method called electrical impedance tomography (EIT) can track how air is distributed in the lungs of adults with lung diseases and healthy volunteers and how those results match standard spirometry.

  Recruiting University Hospital Olomouc · Olomouc · NCT07356076

• Mosliciguat added to inhaled treprostinil for pulmonary hypertension from ILD

  This trial tests whether adding inhaled mosliciguat to your inhaled treprostinil is safe and tolerable for people with pulmonary hypertension caused by interstitial lung disease.

  Recruiting at 13 sites Phase 2 Pulmovant, Inc. · Santa Barbara, California and 12 other locations · NCT07333183

• Collecting lung sound recordings using Eko digital stethoscopes in clinic

  This project will try to teach computer programs to recognize wheeze, crackles, rhonchi, stridor, rales, and cough from stethoscope recordings in adults with suspected or diagnosed lung conditions and in people with normal lungs.

  Recruiting Eko Devices, Inc. · Mumbai, Maharashtra · NCT07270744

• Multi-omics prediction of graft problems after lung transplant

  We will test whether repeated blood and lung-fluid multi-omics tests can spot early graft dysfunction in adults after lung transplantation.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai · NCT07243964

• Recording lung sounds with Eko digital stethoscopes in clinic

  This project will test an AI that listens to lung sounds recorded with Eko digital stethoscopes to find abnormal sounds in people with or without lung disease.

  Recruiting at 2 sites Eko Devices, Inc. · Jacksonville, Florida and 1 other locations · NCT07227376

• Trop2- and EpCAM-targeted PET/CT to help distinguish non-small cell lung cancer

  This project will test whether PET/CT scans that target Trop2 and EpCAM can show protein expression in tumors of people with suspected non-small cell lung cancer.

  Recruiting RenJi Hospital · Shanghai · NCT07026110

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.